Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Study to Evaluate MEDI-534 in Healthy Adults

This study has been completed.
Information provided by:
MedImmune LLC Identifier:
First received: May 26, 2005
Last updated: July 2, 2007
Last verified: July 2007
The primary objective of this study is to describe the safety and tolerability of a single dose of MEDI-534 when administered to healthy adult volunteers.

Condition Intervention Phase
Respiratory Syncytial Virus Infections
Parainfluenza Infections
Drug: MEDI-534
Phase 1

Study Type: Observational
Study Design: Observational Model: Defined Population
Observational Model: Natural History
Time Perspective: Longitudinal
Time Perspective: Prospective
Official Title: Dose-Escalating Study to Evaluate MEDI-534 in Healthy Adults

Resource links provided by NLM:

Further study details as provided by MedImmune LLC:

Estimated Enrollment: 120
Study Start Date: April 2005
Estimated Study Completion Date: December 2005

Ages Eligible for Study:   18 Years to 40 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Male or female ages 18 through 40 years (not yet reached their 41st birthday) on the day of randomization
  • Healthy by medical history and physical examination
  • Available by telephone
  • Signed written informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization obtained from the volunteer
  • Sexually active females, unless surgically sterile or at least 1 year post-menopausal, must have used an effective method of avoiding pregnancy (including oral, implanted, or transdermal contraceptives, intrauterine device (IUD), female condom, diaphragm with spermicide, cervical cap, abstinence, use of a condom by the sexual partner or sterile sexual partner) for at least 30 days prior to dosing of study vaccine, and must agree to continue using such precautions for at least 30 days after dosing; the volunteer must also have a negative serum pregnancy test within 7 days prior to dosing of study vaccine and a negative urine pregnancy test on the day of study vaccine dosing prior to administration
  • Sexually active males, unless surgically sterile, must use an effective method of birth control (condom or abstinence) and must agree to continue using such precautions for at least 30 days after dosing
  • Ability to understand and comply with the requirements of the protocol as judged by the investigator
  • Ability to complete the follow-up period of 6 months following dosing as required by the protocol

Exclusion Criteria:

  • Acute illness on the day of randomization
  • Fever (greater than or equal to 99.5°F oral or greater than or equal to 100.1°F tympanic) and/or respiratory illness (e.g., cough or sore throat) within 7 days prior to randomization
  • Any drug therapy (chronic or other) within 7 days prior to randomization (except for certain medications such as contraceptives, topical [i.e., dermatologic] corticosteroids, or infrequent use of over-the-counter pain relievers, following approval from the sponsor) or expected receipt through 28 days after study vaccine dosing
  • Receipt of immunoglobulin or blood products within 90 days prior to screening or expected receipt through 28 days after study vaccine dosing
  • Receipt of any investigational drug within 60 days prior to randomization or expected receipt during the study period (i.e., through 180 days after study vaccine dosing)
  • Receipt of an approved vaccine within 30 days prior to randomization or expected receipt through 28 days after study vaccine dosing
  • History of immunodeficiency or receipt of immunosuppressive agents, or expected receipt of an immunosuppressive agent through 28 days after study vaccine dosing
  • Close contact at home or in the workplace with children under 2 years of age
  • Household contact who is immunocompromised; volunteer should also avoid close contact with immunocompromised individuals for at least 21 days after vaccination
  • History of hypersensitivity to kanamycin or other aminoglycoside antibiotics (gentamicin, tobramycin, etc.)
  • Previous medical history, or evidence, of an intercurrent or chronic illness that, in the opinion of the investigator, may compromise the safety of the volunteer
  • Any evidence of end organ dysfunction
  • Current, or history of, clinically significant abnormality on electrocardiogram (ECG) (screening ECG must be within 30 days prior to randomization)
  • Evidence of active infection with HIV or hepatitis A, B, or C virus, or serologic evidence of past infection with hepatitis B or C virus
  • At screening (must be within 7 days prior to randomization), any of the following laboratory tests outside of the laboratory normal range: CBC: hemoglobin (Hgb), WBC count, platelet count; AST, ALT, BUN, creatinine; or other abnormal laboratory value in the screening panel that, in the opinion of the principal investigator, may potentially confound analysis of study results
  • Nursing mother
  • History of alcohol or drug abuse in the past 2 years
  • History of medical diagnosis of asthma, reactive airway disease, or chronic obstructive pulmonary disease (COPD)
  • History of any smoking in the past 5 years
  • Previous vaccination against Respiratory Syncytial Virus (RSV) or Parainfluenza Virus Type 3 (PIV3) in a clinical trial
  • Employees of the research center, any individuals involved with the conduct of the study, or family members of such individuals
  • Any condition that, in the opinion of the investigator, might interfere with study vaccine evaluation
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00111878

United States, Ohio
Children's Hospital
Columbus, Ohio, United States, 43205
United States, Pennsylvania
Primary Physicians Research
Pittsburgh, Pennsylvania, United States, 15241
United States, Texas
Radiant Research
Dallas, Texas, United States, 75247
Sponsors and Collaborators
MedImmune LLC
Study Director: Margarita Gomez, MD MedImmune LLC
  More Information Identifier: NCT00111878     History of Changes
Other Study ID Numbers: MI-CP119
Study First Received: May 26, 2005
Last Updated: July 2, 2007

Keywords provided by MedImmune LLC:
Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3)

Additional relevant MeSH terms:
Communicable Diseases
Virus Diseases
Respiratory Syncytial Virus Infections
Paramyxoviridae Infections
Pneumovirus Infections
Mononegavirales Infections
RNA Virus Infections processed this record on May 25, 2017